Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEN-OM in Relapsed/Refractory AML
NCT04926285Phase 1Completed
- Sponsor
- University of Illinois Chicago
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of homoharringtonine in acute myeloid leukemia (AML) (4 cohorts), sponsored by University of Illinois Chicago. Primary endpoint: Maximum Tolerated Dose at 42 days. Started Jun 2022; status: completed.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04926285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926285.